cancer drug — cancer drug — The Cyprus Oncology Society (OEK) has responded to concerns over delays in the approval of cancer treatment drugs by the Health Insurance Organisation (HIO). These delays have raised significant worries among patients and healthcare professionals alike.
On Wednesday, OEK clarified its position, highlighting procedural issues related to the transfer of the nominal requests committee from the Health Ministry to the HIO. This transition, which occurred in May, has been cited as a contributing factor to the delays.
OEK has engaged in consultations aimed at streamlining and improving the drug approval process. Following a meeting with HIO on May 26, both organisations agreed on a scientifically accepted timeline for updating and completing therapeutic protocols. OEK noted that these updates have already resulted in a decrease in the number of nominal requests.
In cases where requests for drugs are rejected, OEK reassured physicians that there is a mechanism in place for appeals to be made to a review board. This process aims to ensure that treating physicians can advocate for their patients effectively.
Amid rising complaints about critical delays, OEK emphasised its commitment to transparency and seriousness in applying the new criteria for drug approval. The society continues to monitor the situation closely and is prepared to intervene further if necessary.
Earlier in May, the issue of obstacles in the oncology drug approval process was brought to light, with oncologists reporting instances of rejections or lack of communication after submitting urgent requests. The society’s proactive stance reflects its dedication to addressing these pressing concerns in the field of cancer treatment.